SRR1084484
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.504
- ANGIOGENESIS+0.460
- INFLAMMATORY_RESPONSE+0.423
- COAGULATION+0.399
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.376
- ALLOGRAFT_REJECTION+0.374
- INTERFERON_GAMMA_RESPONSE+0.360
- INTERFERON_ALPHA_RESPONSE+0.350
- IL2_STAT5_SIGNALING+0.335
- TNFA_SIGNALING_VIA_NFKB+0.331
Top 10 suppressed
- MYC_TARGETS_V2-0.592
- OXIDATIVE_PHOSPHORYLATION-0.492
- DNA_REPAIR-0.481
- MYC_TARGETS_V1-0.468
- UNFOLDED_PROTEIN_RESPONSE-0.376
- PROTEIN_SECRETION-0.354
- E2F_TARGETS-0.322
- G2M_CHECKPOINT-0.304
- MTORC1_SIGNALING-0.297
- MITOTIC_SPINDLE-0.203
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR615934 | GTEX | — | 0.952 |
| 2 | SRR1329885 | GTEX | — | 0.949 |
| 3 | SRR1444932 | GTEX | — | 0.936 |
| 4 | SRR1334033 | GTEX | — | 0.936 |
| 5 | SRR1498482 | GTEX | — | 0.934 |
| 6 | SRR1499630 | GTEX | — | 0.934 |
| 7 | SRR1323536 | GTEX | — | 0.930 |
| 8 | SRR1472150 | GTEX | — | 0.929 |
| 9 | SRR597977 | GTEX | — | 0.929 |
| 10 | SRR1475675 | GTEX | — | 0.928 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.504 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.460 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.423 | Idelalisib | — uncovered |
| COAGULATION | 0.399 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.376 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.374 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.350 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.335 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.331 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.314 | Inavolisib | — uncovered |
| COMPLEMENT | 0.277 | Inavolisib | — uncovered |
| APOPTOSIS | 0.262 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.261 | Idelalisib | — uncovered |
| MYOGENESIS | 0.236 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.208 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.196 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.183 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.173 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.163 | Inavolisib | — uncovered |